Consensus for FY25 revenue is $72.72M. The company also reiterated its FY25 adjusted operating expense guidance of $101M-$105M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences reports Q2 EPS (23c), consensus (28c)
- Sight Sciences Raises Full-Year Revenue Guidance
- Sight Sciences announces results of CUA assessing TearCare system
- Sight Sciences announces publication of 24-month results of SAHARA RCT
- Sight Sciences price target raised to $4 from $3 at Morgan Stanley